As exciting as CAR-T is, there are still myriad challenges preventing it from reaching its full potential. Jenna Balestrini, head of strategy and business development at Draper, gives us her views on the biggest barriers to wider usage of these innovative treatments and how to overcome them.
Is CAR-T living up to its promise yet?
The promise of CAR-T is that we can have a single-dose curative solution to treat cancer, and in some ways that is true. There are some cases where a patient (such as Emily Whitehead) was dosed with an autologously-sourced cellular therapy after traditional approaches of radiation and chemo failed, and that cell therapy eradicated cancer in their body.
In that way CAR-T has and is living up to its promise as a curative solution. However, this is not the case for the majority of patients who receive this therapeutic. There are a number of issues including relapse, lack of specificity, limited response, toxicity and side effects. Also, there is a general lack of patient access, especially outside of the indications already approved for the two available cell therapies (Yescarta and Kymriah). Unless a patient is lucky enough to get into a certain trial, under certain care, with a certain kind of cancer, and with a certain kind of genetic predisposition, CAR-T may not work for them.
What needs to be done to fulfill the promise of CAR-T are two things. As a scientific community, we need to think more critically about ways we can broaden the abilities of these biologic agentsthese living cell therapiesto treat not just the immediate hematologic blood cancers but also those patients who have gone through multiple rounds of chemotherapy and radiation, which can seriously damage their initial blood material.
We also need to make a system that is much more one-size-fits-all in terms of its capability of treating cancer. So, the starting material needs to be better, and the biology needs to be more specific. For example, in the case of solid tumors, you need to have a scenario where the cell-based therapy doesnt introduce rejection via either graft-versus-host or host-versus-graft disease. We need to have a scenario where if you have a patient population that doesnt have, say, enough healthy T-cells to begin with, or have enough healthy blood material to work with, we will have a source for that starting material.
What are the biggest remaining unmet needs for patients when it comes to CAR-T?
There are both scientific and business needs that must be understood for these therapies.
The unmet scientific need is understanding why some of these CAR T-cell therapies work and why some dont. As scientists, we need to understand why certain patients respond better, and why we have scenarios in which we can readily adapt these therapeutics for some kinds of cancer but not others. Finally, we need to be able to create biologics that are readily available so that patients can get them when they are initially sick and not after multiple rounds of other options, like chemotherapy and radiation.
There are a large number of studies that show once a patient completes one to two rounds or more of chemotherapy or radiation, their cells are unable to efficaciously be changed into a cell-based therapy. Getting a patients materials earlier would be beneficial. For example, the first time you, as a patient, are diagnosed with cancer, you could have your cells removed and made into a therapeutic, and that would give you a much greater chance for the therapy to be successful. It would also avoid the current situation where your starting material is damaged through rounds of chemotherapy.
In terms of unmet business needs, it is safe to say that these customised immunotherapies are on the brink of revolutionizing how we treat cancer. The commercially approved applications of CAR-T therapies are currently limited to treating just a few kinds of blood cancers, and even these indications require a patient to have undergone several other therapies unsuccessfully. The reality is that when we do develop therapies for larger patient indications, the current healthcare system cannot afford them. Consider the cost of treating 300,000 cancer patients a year, roughly half of those that die from their disease. At $373,000 per patient, the increased burden to the healthcare system would not be sustainable. This cost does not include other associated costs from providing the therapy to the patient hospitalisation, medical support, etc. The unmet need is having a means to manufacture therapeutics at high volume, in significantly less time (i.e. less than 3 days), and at significantly lower cost per therapy. Patient access to these potentially life-saving therapies will require that the costs do not significantly increase the burden on the established healthcare systems.
What are some other barriers to widespread adoption of CAR-T and accessibility for patients?
Other barriers center on patient access to the therapy. For instance, one barrier is how clinical trials are set up, which patient cohorts are chosen and therefore are the contingency that are approved for the therapy use, and ultimately what patients are allowed to have access to them.
Another barrier is the current approach to introducing CAR T-cell therapy only after other treatment options are exhausted. This is a big challenge because its not just about the patients starting material but its about how sick the patient is once they get to you. A patient may have gone through seven rounds of chemotherapy and radiation, and now they are compromised. If we can make CAR-T a front-line therapy, it would make it more accessible and affordable.
What makes CAR-T treatments so expensive? Are there any ways to reduce costs?
One of the reasons CAR-T treatments are so expensive is that the industry does not have an automated, systematic manufacturing process, and because of that, there is an over-reliance on using instrumentation and processes that have been borrowed from other therapies, like blood banking or stem cell transplantation. Most cell therapy manufacturing processes came out of academic institutions. In academia, your touch labor is typically grad students and therefore is inexpensive, while the touch labor in industry is trained professionals and comes at a much higher cost. The high degree of touch labor also contributes to a breakdown in therapy development and hinders its scalability. Tissue engineering, as a field, suffered broadly for these exact reasons.
What difficulties exist in manufacturing CAR-T therapies? How are they affecting access?
CAR T-cells are a promising therapy, but the current state of biomanufacturing is very complex, expensive and time-consuming, often requiring multiple rooms, highly skilled technicians and many instruments. The process for developing CAR T-cell therapies involves gathering T cells from the cancer patients blood, re-engineering them in a lab so they will recognise cancer cells as an enemy and then reintroducing these enriched T cells to the patients body. The current price tag for a single treatment is $450,000. The typical timeframe is 12-17 days.
One reason for this bioprocessing bottleneck is that manufacturers are using equipment thats been retrofitted from other purposes, and then strung them together. With each step in the process, manufacturers typically have to conduct extra quality control measures, which can result in lost time and material and significant expense.
Whats needed is a bioprocessing platform that can help cell therapy developers bring their therapies to market more quickly, safely and affordably.
Draper is working to develop microfluidic platforms that will perform key steps of the CAR T-cell manufacturing process, as well as processes for other types of cell therapies. Innovations include a technique known as acoustophoresis for separating and enriching the immune system cell population that includes T cells using sound energy, as well as a platform for accelerating the process for transferring genetic material into T cells from the current one-to-three days to less than a day.
The goal of these microfluidic technologies is to create improvements in the cell therapy manufacturing process by combining fluidic control, precision and the ability to scale to higher throughput systems for easy integration with existing manufacturing equipment.
What are your future plans for the technology?
I can imagine a scenario where Draper is not just making devices that manufacture cell-based therapies but going further by incorporating artificial intelligence (e.g., machine learning) into these devices. This intelligence would enable us to not just study and learn from the data that is being extracted from our devices but also inform the process. I think thats the future of really smart engineering.
Read the rest here:
Q&A: Draper's Jenna Balestrini on the future of CAR-T - - pharmaphorum
- Stem Cell Therapy Market Comprehensive Analysis, Growth Forecast From 2020 To 2026 - Cole of Duty - July 2nd, 2020
- Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Cole of Duty - July 2nd, 2020
- Recovering from Cancer, a Stem Cell Transplant and Coronavirus - Cancer Health Treatment News - July 2nd, 2020
- Cancer Stem Cell Therapy Industry 2020: Global Market Trends, Size, Share, Growth Applications, SWOT Analysis by Top Key Players and Forecast Report... - July 2nd, 2020
- Adipose Derived Stem Cell Therapy Market includes Production and Market Share by Type (2020-2026) - Cole of Duty - July 2nd, 2020
- Ionis, leading MS researcher throw antisense at a new type of brain cells - Endpoints News - July 2nd, 2020
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise - July 2nd, 2020
- Canine Arthritis Treatment Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast-... - July 2nd, 2020
- Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results - Business Wire - July 2nd, 2020
- Global Microcarrier System Market to Record Significant Rise in Revenue Share Owing to the Augmenting Demand in COVID 19 Pandemic - 3rd Watch News - July 2nd, 2020
- R3 International Offering New Program for Stem Cell Therapy for Liver Failure in Mexico - Yahoo Finance - June 30th, 2020
- Pembrolizumab Approved for First-Line Treatment of Patients With Colorectal Cancer and Key Mutations - AJMC.com Managed Markets Network - June 30th, 2020
- Covid-19 outbreak imparts profitable opportunities to Stem Cell Therapy market; demand to remain high post pandemic - Jewish Life News - June 30th, 2020
- Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in... - June 30th, 2020
- Research Antibodies Market To Reach USD 5.33 Billion By 2027 | Reports and Data - GlobeNewswire - June 30th, 2020
- Hematopoietic Stem Cells Transplantation (HSCT) Market Key Manufactures And Chance Analysis-Kite Pharma, Thermo Fisher Scientific, CellGenix... - June 30th, 2020
- Benefit From CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell ALL - Hematology Advisor - June 30th, 2020
- COVID-19: UAE treats 2000 virus patients with novel stem cell therapy - Gulf News - June 30th, 2020
- UAE stem cell therapy treats over 2000 coronavirus patients, 1200 fully recover - Khaleej Times - June 30th, 2020
- Innovative treatments that harnesses bodys own immune cells to fight cancer now offered at Jimmy Everest Center - KFOR Oklahoma City - June 30th, 2020
- Vitro Bio-Pharma 2nd Quarter Ended April 30th 2020 Financial Results of Operations and Shareholder Letter - Stockhouse - June 30th, 2020
- Stem Cell Therapy Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 - Apsters News - June 30th, 2020
- Animal Stem Cell Therapy Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic And Non-Economic Aspects By... - June 30th, 2020
- Canine Arthritis Treatment Market: 2020 Global Opportunities, Key Players, Competitive and Regional Analysis by Forecast 2025 - Cole of Duty - June 30th, 2020
- Global Covid-19 impact on Stem Cell Banking Market Trends, Analysis by Application and Region by 2025| CCBC,CBR,ViaCord,Esperite - 3rd Watch News - June 30th, 2020
- Osteonecrosis Treatment Market Estimated To Witness a Phenomenal Growth by 2027 | Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd.... - June 30th, 2020
- Global Macular Degeneration Treatment Market Opportunities, Applications, Drivers, Limitations, Top Companies, Countries, & Forecast 2026|Adverum,... - June 30th, 2020
- GoLiver Therapeutics Receives a Positive Scientific Advice from the European Medicines Agency (EMA) on its Clinical Development and Biomanufacturing... - June 30th, 2020
- Stem cell therapy: why we need to be suspicious about cure-all claims - The Irish Times - June 24th, 2020
- Should You Delay Cancer Treatment Because of COVID-19? Study Says Most Treatments Dont Worsen Coronavirus Infection - On Cancer - Memorial Sloan... - June 24th, 2020
- Over $8M in 2020 Stem Cell Funding Awards Continue to Fuel Marylands Leading Cell Therapy Industry - BioBuzz - June 24th, 2020
- TP53, KMT2D Abnormalities Linked With Poor Prognosis in MCL - Targeted Oncology - June 24th, 2020
- Karyopharm Announces Publication of XPOVIO (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology - GlobeNewswire - June 24th, 2020
- Stem Cell Therapy Market 2020: Industry Growth, Competitive Analysis, Future Prospects and Forecast 2025 - 3rd Watch News - June 24th, 2020
- Century Therapeutics Announces Acquisition of Empirica Therapeutics - Business Wire - June 24th, 2020
- Cell Therapy Market 2020 Trend, Growth, Latest Technology & Application Analysis and Global Industry Opportunities Forecast to 2025 - Cole of Duty - June 24th, 2020
- Coronavirus and sex hormones baldness may be a risk factor and anti-androgens a treatment - The Conversation AU - June 24th, 2020
- $14M Federal Grant to Research CAR-T Gene Therapy to Cure HIV - POZ - June 24th, 2020
- Glioblastoma Multiforme Treatment (GBM) Market: Rise in Awareness Regarding Cancer and Novel Therapies to Boost the Market - BioSpace - June 24th, 2020
- 4D physiologically adaptable cardiac patch: A 4-month in vivo study for the treatment of myocardial infarction - Science Advances - June 24th, 2020
- Why are more bald men in hospital with coronavirus? The answer could hold a treatment - ABC News - June 24th, 2020
- SFARI | SFARI workshop explores challenges and opportunities of gene therapies for autism spectrum disorder - SFARI News - June 24th, 2020
- Impact Analysis of Covid-19 On Osteonecrosis Treatment Market Growth and Evolution During 2020-2027 | Bone Therapeutics, Enzo Biochem Inc., and... - June 24th, 2020
- USC scientists use brain organoids to study intellectual disability, with support from the SynGAP Research Fund - USC News - June 24th, 2020
- Cell Therapy Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 by Leading Key Players - 3rd Watch... - June 24th, 2020
- Cell Therapy Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report 2020-2025 - 3rd Watch News - June 24th, 2020
- Cytovia Therapeutics, Inc Adds Two Industry Leaders to Its Board of Directors - BioSpace - June 24th, 2020
- Animal Stem Cell Therapy Market Statistics, Opportunities, Demand, Forecast to 2026 | Study with COVID-19 Impact - 3rd Watch News - June 21st, 2020
- Animal Stem Cell Therapy Market Exhaustive Analysis Strategic Assessment and Forecast Till 2026 - Owned - June 21st, 2020
- Stem Cell Alopecia Treatment Market 2020 Key Players, Share, Trend, Segmentation and Forecast to 2026 - Cole of Duty - June 21st, 2020
- Our girl fought for life on a ventilator to survive coronavirus now stem cell donor is her only chance to b - The Sun - June 21st, 2020
- World Sickle Cell Day 2020: Know The Types, Symptoms, Causes And Treatment - NDTV - June 21st, 2020
- Stem Cell Therapy Market Key Players, SWOT Analysis, Dynamics, Drivers, Key Indicators and Forecast to 2026 - Owned - June 21st, 2020
- Rapid Unit Sales of Oncology Drugs to Account for Incremental Revenues in the Global Market - Cole of Duty - June 21st, 2020
- Electrical Stimulation Therapy Market Analysis, Trends and Forecast to 2026 - Jewish Life News - June 21st, 2020
- Stem Cell Banking Market Recent Developments and Growth Strategies Adopted by Top Key Players Worldwide and Assessment to 2020-2025 - Cole of Duty - June 21st, 2020
- 'Heart-in-a-dish' to study the effects of coronavirus - Cambridge Network - June 21st, 2020
- Report explores the Bone Grafts Market likely to emerge over a period of 2015 to 2021 - 3rd Watch News - June 21st, 2020
- Blood and Bone Marrow Cancer Treatment Market Revenue, Growth Rate, Customer Needs, Trend, Manufacturers and Forecast to 2026 - CueReport - June 21st, 2020
- Nick Corderoros wife Amanda Kloots sees husband for the first time in 79 days as she visits him in hospital - The Irish Sun - June 21st, 2020
- Cell Theraputics Market 2020 2025 analysis examined in new Cell Theraputic - News by aeresearch - June 21st, 2020
- Wound Care Biologics Market Expected to Witness High Growth over the Forecast Period 2020 2025 - Cole of Duty - June 21st, 2020
- 2020 Growth: Thalassemia Treatment Market 2020 Industry Research, Segmentation, Key Players Analysis and Forecast to 2025 - Cole of Duty - June 21st, 2020
- Biomedicals big year: Grants fund research on skin, heart cells, cancer and more - Binghamton University - June 19th, 2020
- Cell and gene therapy-focused OpenCell Technologies hires MilliporeSigma executive Kevin Gutshall as new CEO - PRNewswire - June 19th, 2020
- Insight to CV Risks of CAR T-Cell Therapy - MedPage Today - June 19th, 2020
- COVID-19: Potential impact on Musculoskeletal Disorder Stem Cell Therapy Market Estimated to Record Highest CAGR by 2019-2025 - Personal Injury Bureau... - June 19th, 2020
- Orca Bio breaches the surface with $192M for 'high precision' cell therapies - FierceBiotech - June 19th, 2020
- Impact of COVID-19 on Avascular Necrosis Market Potential Growth and Forecast Period 2020-2027 | By Leading Players Boehringer Ingelheim GmbH, Bayer... - June 19th, 2020
- Trending news Covid-19 impact on Stem Cell Therapy Market Trending news Covid-19 impact on Stem Cell Therapy Market Key Vendors Countries and Forecast... - June 16th, 2020
- CRISPR and Vertex show durability of gene-editing therapy, hoping for one and done treatment - FierceBiotech - June 16th, 2020
- Race Oncology confirms positive results from Bisantrene drug trial on patients with advanced acute myeloid leukaemia - Small Caps - June 16th, 2020
- COVID-19 and cancer care - Pursuit - June 16th, 2020
- Biogen's NURTURE Data, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha - June 16th, 2020
- Stem Cell Therapy Market Growth Trends, Key Players, Competitive Strategies and Forecasts to 2026 - Jewish Life News - June 14th, 2020
- Bit Bios enter button for the keyboard to the software of life nabs the company $41.5 million - TechCrunch - June 14th, 2020
- Could pressure for COVID-19 drugs lead the FDA to lower its standards? - The Conversation US - June 14th, 2020
- Vancouver Island father dies of leukemia after battle to find mixed-race stem cell donor - Lake Country Calendar - June 14th, 2020
- Royalty Pharma Acquires Partial Royalty Interest on Prevymis From AiCuris Anti-Infective Cures GmbH - Citybizlist Real Estate - June 14th, 2020
- OncoImmune, Inc. Reports Progress on its Phase III Clinical Trial testing CD24Fc for Severe and Critical COVID-19 - Business Wire - June 14th, 2020